B. E. Johnson
21 works · 617 citations · h-index 11
Top works
- Molecular Genetic Analysis Reveals Chromosomal Deletion, Gene Amplification, and Autocrine Growth Factor Production in the Pathogenesis of Human Lung Cancer
- Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
- Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
- Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).
- Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: The End of the Beginning
- A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC
- Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC
- Association of chromosome 11 locus D11S12 with histology, stage, and metastases in lung cancer.
- A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
- Is More Better? Chemotherapy for Patients With Extensive-Stage Small-Cell Lung Cancer
- Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib
- Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy.
- Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).
- Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.
- O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma
- Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI’s vs. chemotherapy
- 9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
- Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib.
- Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib
- Smoking history, drug toxicity, and survival in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs